The MTA would specify the goal of the remyelination testing. Missling would know. It would be an opportunity for them to check out the combo of their drug and 2-73, to see if results were more robust and I'm sure they'd also be doing testing about the weaknesses of opicinumab. It was a large trail, over 400 patients, so they probably had anecdotal evidence that the drug was going to fail.
What I want to see at Bio 2017 is the trial extension data and the genetic factors that will be built into the trials.
IMO - if anything works out with Biogen they will pump it as a rescue of their drug and call the shots.
News 
Market Data 
Discover 
